ALK inhibitors: plateauing systemic and intracranial activity?
Mené sur 255 patients atteints d'un cancer du poumon non à petites cellules ALK+ de stade avancé ou métastatique (dont 94 présentant des métastases cérébrales), cet essai international de phase III évalue l'activité antitumorale et la toxicité du céritinib
Rearrangements between ALK and fusion partners (such as EML4, among others) drive proliferation in 5% of non-small-cell lung cancers (NSCLCs). Oral ALK inhibitors are the exemplars for the development of precision treatments in NSCLC. The first-generation ALK inhibitor crizotinib, which entered the thoracic oncology clinic in the late 2000s, was a multitargeted inhibitor of not only ALK, but also MET and ROS1. Crizotinib has been shown to induce consistent clinical and radiographic responses in patients whose NSCLC harbours ALK rearrangements, ROS1 rearrangements, high-level MET amplification, or MET exon 14 skipping mutations.